1. Editas Medicine to host webinar on September 2, 2025. 2. Webinar will announce lead in vivo development candidate. 3. Company focuses on CRISPR/Cas gene editing for serious diseases. 4. Webcast will be accessible live and archived online. 5. Editas aims for transformative medicines through gene editing.
The upcoming webinar indicating a lead in vivo candidate can boost investor confidence, similar to previous announcements leading to stock price surges in biotech.
The announcement of a lead development candidate is significant, influencing perceptions of Editas' future potential and investment appeal.
The immediate impact is expected around the webinar date, with potential longer-term effects based on candidate success.
CAMBRIDGE, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it will host a webinar on Tuesday, September 2, 2025, at 8:00 a.m. ET to announce the selection of its lead in vivo development candidate.
Webinar Presentation Details:
The live and archived webcast of the Company's webinar presentation will be accessible through this webcast link, or through the Events & Presentations page of the "Investors" section of the Company's website.
A replay of the webinar will be available upon conclusion of the webinar in the Investors section of the Editas Medicine website at https://www.editasmedicine.com/.
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of transformative in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute's Cas12a patent estate and Broad Institute and Harvard University's Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.
Investor and Media Contacts: ir@editasmed.com media@editasmed.com
